Develops cancer treatments using targeted drug-delivery devices.
Jun 2026Revenue $1.98M/yrExpenses $15.5M/yr
No trendCash runway ≈ 10 months from Jun 2026
Figures by year
When will RenovoRx be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $1.98M and expenses $15.5M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $1.12M | $13.6M | −$12.5M |
| Dec 2024 | $43.0K | $11.0M | −$11.0M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.